Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920493 | 1.00 | TRPM8 (0.47) | TRPM8GPR139ACHEFFAR1PTGS1 | |
| SCHEMBL18920508 | 1.00 | TRPM8 (0.47) | TRPM8GPR139ACHEFFAR1PTGS1 | |
| SCHEMBL18920458 | 0.85 | ACHE (0.44) | ACHEPTGS1GLSBCHEMARK4 | |
| SCHEMBL29173105 | 0.82 | TDP1 (0.53) | TRPM8ACHEPTGS1 | |
| SCHEMBL29173106 | 0.82 | TDP1 (0.53) | TRPM8ACHEPTGS1 | |
| SCHEMBL29537690 | 0.81 | PTGS1 (0.65) | GPR139FFAR1PTGS1 | |
| SCHEMBL1759907 | 0.81 | PTGS1 (0.65) | GPR139FFAR1PTGS1 | |
| SCHEMBL1991313 | 0.81 | PTGS1 (0.65) | GPR139FFAR1PTGS1 | |
| SCHEMBL761250 | 0.80 | TRPM8 (0.46) | TRPM8GPR139FFAR1PTGS1CTSA | |
| SCHEMBL1275951 | 0.80 | CTSA (0.47) | TRPM8GPR139FFAR1PTGS1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349965-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| CN-108349965-A | 1,3,4- thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLRX3 | TRPM8 4432/4885GPR139 3364/4885ACHE 3475/4885 |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLRX3 | TRPM8 4432/4885GPR139 3364/4885ACHE 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.